Vontobel Holding Ltd. Cuts Stock Position in Insulet Co. (NASDAQ:PODD)

Vontobel Holding Ltd. trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD) by 17.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,323 shares of the medical instruments supplier’s stock after selling 501 shares during the period. Vontobel Holding Ltd.’s holdings in Insulet were worth $541,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. acquired a new stake in shares of Insulet in the first quarter valued at about $29,000. International Assets Investment Management LLC purchased a new position in Insulet in the 2nd quarter worth approximately $32,000. UMB Bank n.a. grew its position in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. CVA Family Office LLC raised its stake in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares during the period. Finally, Massmutual Trust Co. FSB ADV lifted its position in shares of Insulet by 159.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 156 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PODD. BTIG Research lifted their price target on shares of Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Canaccord Genuity Group lifted their target price on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Citigroup increased their price target on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Raymond James raised their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Finally, Barclays upped their target price on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $242.29.

Insulet Trading Down 0.0 %

NASDAQ PODD opened at $236.48 on Tuesday. The firm has a market capitalization of $16.58 billion, a PE ratio of 43.00, a price-to-earnings-growth ratio of 4.35 and a beta of 1.21. Insulet Co. has a one year low of $128.68 and a one year high of $243.98. The company has a 50-day simple moving average of $218.20 and a 200-day simple moving average of $197.28. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the company posted $0.38 earnings per share. On average, equities analysts forecast that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.